Form 4: Nautilus Biotechnology Executive Acquires 160,000 Stock Options
SEC Form 4 Filing
Nicholas A. Nelson, CBO & Senior VP of Business Development at Nautilus Biotechnology, acquired 160,000 stock options on March 1, 2024.
Summary
- Nicholas A. Nelson, the CBO & Senior VP, Business Development of Nautilus Biotechnology, Inc., filed a Form 4 on March 5, 2024.
- The filing reports a transaction that occurred on March 1, 2024, where Nelson acquired 160,000 stock options.
- The exercise price of these options is $2.72.
- The options vest over time, with 25% vesting on January 1, 2025 (one year after the Vesting Commencement Date of January 1, 2024), and the remainder vesting monthly thereafter, subject to continuous service as a 'Service Provider'.
- The options expire on March 1, 2034.
Sentiment
Score: 6
Explanation: Neutral sentiment as it's a standard executive compensation practice. The grant itself is neither overwhelmingly positive nor negative.
Positives
- The acquisition of stock options by a company executive can be seen as a positive sign, indicating confidence in the company's future performance.
Future Outlook
The vesting schedule indicates a long-term incentive plan for the executive, aligning their interests with the company's long-term success.
Industry Context
Stock option grants are a common form of executive compensation in the biotechnology industry, used to attract and retain talent and align their interests with shareholder value.
Comparison to Industry Standards
- Stock option grants are a standard component of compensation packages for executives in biotechnology companies.
- The size of the grant and the vesting schedule are typical for executives at Nelson's level.
- Comparable companies such as Pacific Biosciences, Twist Bioscience, and Quantum-Si also utilize stock options as part of their executive compensation packages.
Stakeholder Impact
- Shareholders may view the stock option grant as a way to incentivize management to increase shareholder value.
- Employees may see this as a positive sign of the company's commitment to its leadership.
Key Dates
| Date | Description |
|---|---|
| 2024-01-01 | Vesting Commencement Date |
| 2024-03-01 | Date of transaction: Acquisition of 160,000 stock options |
| 2024-03-05 | Date of Form 4 filing |
| 2025-01-01 | 25% of the options vest |
| 2034-03-01 | Expiration date of the stock options |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.